Published in J Heterocycl Chem on June 01, 2016
An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain (1992) 9.17
Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell (2009) 3.61
Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem (2000) 3.22
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation. Neuron (2011) 2.42
Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J (2007) 1.89
The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem (1999) 1.84
Bi- or multifunctional opioid peptide drugs. Life Sci (2009) 1.69
Multiple opiate receptors: déjà vu all over again. Neuropharmacology (2004) 1.59
Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J (2006) 1.46
Receptor heteromerization and drug discovery. Trends Pharmacol Sci (2010) 1.37
Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther (1992) 1.32
The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.26
Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci (2003) 1.24
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem (2007) 1.21
Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors. Bioorg Med Chem Lett (2007) 1.15
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth (2009) 1.15
Polyvalency: a promising strategy for drug design. Biotechnol Bioeng (2008) 1.13
Development of potent μ and δ opioid agonists with high lipophilicity. J Med Chem (2010) 1.08
New paradigms and tools in drug design for pain and addiction. AAPS J (2006) 1.07
Synaptic mechanism for functional synergism between delta- and mu-opioid receptors. J Neurosci (2010) 1.06
N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers. Proc Natl Acad Sci U S A (2011) 1.05
Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2,D-Pen5]enkephalin. Eur J Pharmacol (1989) 1.03
Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J (2006) 1.02
Bivalent ligands for G protein-coupled receptors. Curr Pharm Des (2004) 0.99
Opiate and peptide interaction: effect of enkephalins on morphine analgesia. Eur J Pharmacol (1980) 0.98
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96
Multiple ligands in opioid research. Protein Pept Lett (2008) 0.95
A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. Bioorg Med Chem Lett (2009) 0.94
Design of multivalent ligand targeting G-protein-coupled receptors. Curr Pharm Des (2009) 0.94
Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer. Br J Pharmacol (2010) 0.94
Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists. Eur J Pharmacol (1989) 0.90
Design strategies for bivalent ligands targeting GPCRs. ChemMedChem (2011) 0.89
Receptor dimerization--rationale for the design of bivalent ligands. Curr Top Med Chem (2007) 0.85
Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. Bioorg Med Chem (2011) 0.83
Opioid and melanocortin receptors: do they have overlapping pharmacophores? Biopolymers (2008) 0.82
Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Life Sci (2013) 0.82
Proton sharing and transfer in some zwitterionic compounds based on 4-oxo-4-((1-phenethylpiperidin-4-yl)(phenyl)amino)alcanoic acids. CrystEngComm (2010) 0.81
Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor. IUBMB Life (2010) 0.80
Development of mu/delta opioid ligands: enkephalin analogues containing 4-anilidopiperidine moiety. Adv Exp Med Biol (2009) 0.77
Fragment-based ligand discovery meets phage display. ACS Chem Biol (2007) 0.76
Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. Eur J Med Chem (2010) 0.76
Mix and match: heterodimers and opioid tolerance. Neuron (2011) 0.76
Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neurosci Lett (2013) 1.45